Format

Send to:

Choose Destination
See comment in PubMed Commons below
Sci Rep. 2014 Nov 6;4:6881. doi: 10.1038/srep06881.

Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus.

Author information

  • 1Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada, R3E 0J9.
  • 2Special Pathogens Program, Canadian Science Center for Human and Animal Health, Public Health Agency of Canada, Winnipeg, Canada, R3E 3R2.
  • 3CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, P.R. China.
  • 41] Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada, R3E 0J9 [2] Special Pathogens Program, Canadian Science Center for Human and Animal Health, Public Health Agency of Canada, Winnipeg, Canada, R3E 3R2 [3] Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada, R3E 0J9 [4] Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.

Abstract

Ebola virus (EBOV) causes severe viral hemorrhagic fever in humans and non-human primates, with a case fatality rate of up to 88% in human outbreaks. Over the past 3 years, monoclonal antibody (mAb) cocktails have demonstrated high efficacy as treatments against EBOV infection. One such cocktail is ZMAb, which consists of three mouse antibodies, 1H3, 2G4, and 4G7. Here, we present the epitope binding properties of mAbs 1H3, 2G4, and 4G7. We showed that these antibodies have different variable region sequences, suggesting that the individual mAbs are not clonally related. All three antibodies were found to neutralize EBOV variant Mayinga. Additionally, 2G4 and 4G7 were shown to cross-inhibit each other in vitro and select for an escape mutation at the same position on the EBOV glycoprotein (GP), at amino acid 508. 1H3 selects an escape mutant at amino acid 273 on EBOV GP. Surface plasmon resonance studies showed that all three antibodies have dissociation constants on the order of 10(-7). In combination with previous studies evaluating the binding sites of other protective antibodies, our results suggest that antibodies targeting the GP1-GP2 interface and the glycan cap are often selected as efficacious antibodies for post-exposure interventions against EBOV.

PMID:
25375093
[PubMed - indexed for MEDLINE]
Free full text

Publication Types, MeSH Terms, Substances

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk